NCT05164406

Impact of Blood Salvage Therapy on Outcomes After Oncologic Liver Surgery

Impact of Blood Salvage Therapy During Oncologic Liver Surgeries on Allogenic Transfusion Events, Survival and Recurrence

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 106 (actual)
• Sponsor: Université de Sherbrooke · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: —

Summary

A before and after trial comparing the systematic use of blood salvage therapy with leucocyte filter during oncologic liver resections. Recurrence, survival, allogenic transfusion rates and surgical outcomes are compared with a representative historic cohort.

Detailed description

Blood salvage therapy in oncologic liver surgery is seldom used based on unproven concerns about the safety of the technique regarding potential cancer dissemination or recurrence. Nevertheless, the technique has proven advantages in other surgical settings regarding the allogenic transfusion outcomes. Allogenic blood transfusion has been scientifically proven to worsen prognosis in oncologic surgery. This study compares a cohort of patients systematically exposed the blood salvage therapy to one comparable cohort without the therapy and outcomes regarding transfusion rates, post-operative Hb measurement, recurrence, overall survival, and post-operative adverse events.

Conditions

• Liver Neoplasms

Interventions

Type	Name	Description
PROCEDURE	Blood salvage therapy	In the blood salvage group, blood is systematically given back when the minimal amount of blood loss required for reprocessing is met

Timeline

• Start date: 2018-01-01
• Primary completion: 2019-08-01
• Completion: 2021-02-28
• First posted: 2021-12-20
• Last updated: 2023-05-31

Locations

1 site across 1 country: Canada